Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2010 - 2026)

Biocryst Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at $412.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 77887.15% year-over-year to $412.6 million; the trailing twelve-month figure through Mar 2026 stood at $62.1 million (up 1584.03% YoY), and the FY2025 full-year result was -$349.9 million, down 5974.14% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $412.6 million, up from -$218.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $412.6 million in Q1 2026, with the low at -$218.0 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $10.4 million across 5 years, with a median of $529000.0 in 2025.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities plunged 5320.54% — and 2026, when it jumped 77887.15%.
• Biocryst Pharmaceuticals' Cash from Financing Activities stood at $4.2 million in 2022, then sank by 175.57% to -$3.2 million in 2023, then fell by 26.73% to -$4.0 million in 2024, then sank by 5320.54% to -$218.0 million in 2025, then surged by 289.28% to $412.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $412.6 million (Q1 2026), -$218.0 million (Q4 2025), and -$58.8 million (Q3 2025), per Business Quant data.